Aceclidine+Brimonidine combination ophthalmic solution + Aceclidine ophthalmic solution + Placebo (Vehicle) ophthalmic solution
Phase 3Completed 0 watching 0 views this week๐ Rising
69
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 24
Phase 35
ApprovedIndication / Disease
Presbyopia
Conditions
Presbyopia, Near Vision, Miosis, Eye Diseases
Trial Timeline
Sep 27, 2023 โ Jan 27, 2025
NCT ID
NCT06045299About Aceclidine+Brimonidine combination ophthalmic solution + Aceclidine ophthalmic solution + Placebo (Vehicle) ophthalmic solution
Aceclidine+Brimonidine combination ophthalmic solution + Aceclidine ophthalmic solution + Placebo (Vehicle) ophthalmic solution is a phase 3 stage product being developed by LENZ Therapeutics for Presbyopia. The current trial status is completed. This product is registered under clinical trial identifier NCT06045299. Target conditions include Presbyopia, Near Vision, Miosis.
Hype Score Breakdown
Clinical
27
Activity
18
Company
2
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06045299 | Phase 3 | Completed |
Competing Products
14 competing products in Presbyopia
Other Products from LENZ Therapeutics
Aceclidine+Brimonidine combination ophthalmic solution + Placebo + Aceclidine Ophthalmic SolutionPhase 3
69
Aceclidine+Brimonidine combination ophthalmic solution + Aceclidine ophthalmic solution + VehiclePhase 3
69
Aceclidine+Brimonidine combination ophthalmic solution + Aceclidine ophthalmic solution + BrimonidinePhase 3
69
Aceclidine+Brimonidine combination ophthalmic solution + Aceclidine ophthalmic solution + Vehicle Proprietary Ophthalmic SolutionPhase 2
44
PRX-100 + PlaceboPhase 2
44